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Abstract
Background: DNA methylation (DNAm) age was found to be an indicator for all-cause mortality, cancer incidence,
and longevity, but no study has involved in the associations of DNAm age with the prognosis of breast cancer.
Methods: We retrieved information of 1076 breast cancer patients from Genomic Data Commons (GDC) data portal
on March 30, 2017, including breast cancer DNAm profiling, demographic features, clinicopathological parameters,
recurrence, and all-cause fatality. Horvath’s method was applied to calculate the DNAm age. Cox proportional
hazards regression models were used to test the associations between DNAm age of the cancerous tissues and the
prognosis (recurrence of breast cancer and all-cause fatality) with or without adjusting for chronological age and
clinicopathological parameters.
Results: The DNAm age was markedly decelerated in the patients who were premenopausal, ER or PR negative,
HER2-enriched or basal-like than their counterparts. In the first five-year follow-up dataset for survival, every ten-year
increase in DNAm age was associated with a 15% decrease in fatality; subjects with DNAm age in the second (HR:
0.52; 95%CI: 0.29–0.92), the third (HR: 0.49; 95%CI: 0.27–0.87) and the fourth quartile (HR: 0.38; 95%CI: 0.20–0.72) had
significant longer survival time than those in the first quartile. In the first five-year follow-up dataset for recurrence,
every ten-year increase in DNAm age was associated with a 14% decrease of the recurrence; in the categorical
analysis, a clear dose-response was shown (P for trend =0.02) and the fourth quartile was associated with a longer
recurrence free survival (HR: 0.32; 95%CI: 0.14–0.74). In the full follow-up dataset, similar results were obtained.
Conclusions: DNAm age of breast cancer tissue, which associated with menopausal status and pathological features,
was a strong independent predictor of the prognosis. It was suggested that the prognosis of breast cancer was related
to intrinsic biological changes and specific molecular targets for treatment of breast cancer may be implicit.
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Background
Ageing presents numerous progressive changes in mo-
lecular, cellular, tissular and organismal functions, which
ultimately drives various diseases and limits lifespan [1].
Consequently, age has been confirmed to be the stron-
gest demographic risk factor for most common chronic
human diseases, including cancers [2]. Ageing indicates
accumulation of somatic mutations as well as aberrant
epigenetic changes (epimutations) [3, 4]. Based on DNA
methylation data, an age estimator (referred to as
DNAm age) has been developed to accurately estimate
chronological age across multiple normal tissues [5, 6].
An increasing body of literatures reported that the
DNAm age was able to capture the aspects of the bio-
logical age of the underlying normal tissue and predict
the susceptibility to various health outcomes. For ex-
ample, the DNAm age of blood was predictive of all-
cause mortality [7–11], cancer incidence [12–17], and
longevity [10].
For malignant tumor tissues, however, the DNAm age
was not able to estimate the chronological age of the
host [6]. This may be because DNAm pattern in the
clones of cancer origination is different from that of nor-
mal tissue and it only presents the state of ageing in the* Correspondence: renzef@mail.sysu.edu.cn
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tumor cells [18]. It was exhibited that stem cells had the
lowest DNAm age and this age increased when they dif-
ferentiated into more mature cells [6]. Moreover, the
cancer new clones develop with a wide variation, which
consequently induces huge inter- and intra- heterogen-
eity in cancer tissues, including both the genomics and
epigenomics [19]. Therefore, we speculate that the
DNAm age of cancer cells may present the capacity to
differentiate into malignant clones and can predict the
outcome of the disease. Till now, only one study have
involved in the associations of DNAm age in malignant
diseases with the prognosis, while breast cancer was not
included [18]. The role of DNAm age in tumor tissues
in predicting the prognosis of cancer patients is far from
being confirmed.
In the present study, we focused on breast cancer and
comprehensively analyzed whether the DNAm age in
tumor tissues was associated with the prognosis when
taking the chronological age and the clinicopathological
features into account, using the datasets from the Can-
cer Genome Atlas (TCGA) data portal.
Methods
Datasets
We retrieved all available breast cancer DNAm profiles on
Infinium Human Methylation 450 Bead Chip or Human
Methylation 27 Bead Chip (Illumina Inc.) from Genomic
Data Commons (GDC) data portal (https://portal.gdc.can-
cer.gov/) with TCGA datasets using the R/Bioconductor
TCGAbiolinks package [20] (https://www.bioconductor.-
org/). Corresponding demographic characteristics (gender,
chronological age, menopausal status, and race), clinico-
pathological parameters (tumor stage and subtypes), fol-
low up data (recurrence, all-cause fatality) were also
downloaded from GDC on March 30, 2017. Thus, the
present study dataset contains 1085 breast cancer DNAm
profiles for 1076 female patients (9 subjects had double
profiles which were averaged). Other 122 DNAm pro-
files for adjacent normal breast tissues were also in-
cluded in the dataset to demonstrate the accuracy of
the estimation method on chronological age. Only
889of these female breast cancer patients had recur-
rence free survival information which was obtained
from UCSC Xena (http://xena.ucsc.edu/).
DNAm age calculation
We applied Horvath’s method to calculate the DNAm
age [6], which is currently the most robust predictor of
chronological age [21]. Briefly, 353 dinucleotide markers
were selected from 21,369 CpG probes on the Illumina
27 K and 450 K platforms with a penalized regression
model in a large sample (n = 8000), including 51 healthy
tissues and cell types and covering the entire adult life
span. These markers were weighted to estimate the
DNAm age (in units of years). It shows high age correla-
tions (r = 0.96) and small mean deviation from calendar
age (3.6 years) in its validation cohort. Mathematical de-
tails and software tutorials for DNAm age calculation
can be found in the Additional files of Horvath [6]. An
online age calculator (https://dnamage.genetics.ucla.edu)
is available, by which the DNAm ages for the adjacent
normal tissues and the cancerous tissues from the breast
cancer patients in the dataset were obtained.
Statistics
Scatter plots were generated to illustrate the relationship
between chronological age and DNAm age in the adjacent
normal tissues and cancerous tissues. Pearson correlation
coefficient (r) between chronological and DNAm ages
were computed accordingly. Cox proportional hazards re-
gression models were used to test the associations be-
tween DNAm age of the cancerous tissues and the
prognosis (recurrence of breast cancer and all-cause fatal-
ity). Hazard Ratios (HRs) and corresponding 95% confi-
dence intervals (CIs) were calculated. Three models were
applied: 1) no adjustment, 2) adjusted only for chrono-
logical age (continuous), and 3) further adjusted for race,
clinical stage, menopause status, estrogen receptor (ER),
human epidermal growth factor receptor 2 (HER2), and
PAM50 subtype. DNAm age was regarded as either a lin-
ear function expressed by per ten-year increase or cat-
egory of quartile.
Four endpoints were applied to present the prognosis:
1) overall survival (full follow-up), 2) five-year survival
(the first five-year follow-up), 3) overall recurrence free
survival (full follow-up), and 4) five-year recurrence free
survival (the first five-year follow-up). Five-year survival
and recurrence free survival were generated from the
original dataset by censoring patients who died after
five-year follow-up and limiting survival time to 5 years
for patients who survived for more than 5 years.
Stratified analyses for the associations were performed
by race, menopausal status and pathological characteris-
tics of HER2, ER, PAM50 subtype, and clinical stage.
The interactions between DNAm age and stratified vari-
ables were evaluated by adding an interaction term in
the Cox model, which was tested by Wald test. All stat-
istical tests were two-tailed with P < 0.05 considered to
be significant. Statistical analyses were conducted using
R software version 3.3.2 (https://www.r-project.org/).
Results
Relationship between chronological age and DNAm age
As shown in Fig. 1, the Pearson correlation coefficients be-
tween DNAm age and chronological age were 0.85 (p <
0.01) for breast normal tissues and 0.30 (p < 0.01) for breast
cancerous tissues. The median absolute deviations (ranges
of the difference between DNAm age and chronological
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age) were 5.78 (− 24.94 to 12.02) years and 14.72 (− 67.35
to 91.38) years for normal tissues and cancerous tissues,
respectively.
Characteristics and the relationships with DNAm age in
breast cancer tissues
The demographic and clinicopathological characteristics
for 1076 female breast cancer patients were shown in
Table 1. The majority of the patients were over 40 years
old. Chronological age, in a way of categorical variable,
was positively associated with DNAm age. The African
American patients had a significant lower DNAm age
than the whites or others. The DNAm age was markedly
decelerated among the patients who were premeno-
pausal, ER or PR negative, HER2-enriched or basal-like
than their corresponding counterparts.
Associations between DNAm age and prognosis
During the full follow-up period, 151 all-cause deaths
were recorded in all patients and 96 cases recurred in
889 patients with recurrence data. During the first five-
year follow-up period, 98 and 79 patients were recorded
for all-cause deaths and recurrence, respectively.
When survival as an outcome, older DNAm age was
associated with longer survival, and this association was
more evident in the first five-year follow-up dataset, in
which every ten-year increase in DNAm age was associ-
ated with a 15% decrease in fatality in the full adjust-
ment model (HR: 0.85; 95%CI: 0.76–0.96) (Table 2).
Compared with the first quartile, the second (HR: 0.52;
CI: 0.29–0.92), the third (HR: 0.49; 95%CI: 0.27–0.87),
and the fourth quartile (HR: 0.38; 95%CI: 0.20–0.72)
were all associated with a longer survival in the first
five-year follow-up dataset, and the P value for trend
was significant (P = 0.004). In addition, compared with
the first quartile, the combined three upper quartiles
were also associated with a longer survival (HR: 0.47;
95%CI: 0.29–0.76). For all the endpoints, the associa-
tions between DNAm age and breast cancer prognosis
were stronger after adjusted for chronological age.
When recurrence free survival as an outcome, it was
similarly shown that higher DNAm age was associated
with a longer recurrence-free survival (Table 3). Every
ten-year increase in DNAm age was significantly associated
with a 14% decrease of the recurrence for both datasets of
full and five-year follow-up in the full adjustment model.
In the categorical analysis, a significant dose-response rela-
tionship was shown (P for trend < 0.05) and the fourth
quartile was associated with a longer recurrence-free sur-
vival [HR (95%CI): 0.39 (0.19–0.80) and 0.32; 0.14–0.74 for
full follow-up and five-year follow-up, respectively)], al-
though the combined three upper quartiles were not sig-
nificantly associated with recurrence-free survival when
compared with the first quartile.
Stratified analyses were further performed to assess
whether the associations between the DNAm age and
the prognosis of breast cancer were modified by clinical-
pathological characteristics and menopausal status
(Table 4). Although the interactions did not reach the
level of statistical significance, the subgroups showed
considerable differences in HR estimates when stratified
by menopause status. The HR and 95% CI (three upper
combined quartiles vs. first quartile DNAm age) were
0.40 (0.24–0.69) in post-menopausal patients and 0.87
(0.30–2.58) in pre-menopausal patients for overall sur-
vival, and the HR and 95% CI were 0.58 (0.29–1.16) and
1.16 (0.42–3.21) for recurrence-free survival, respect-
ively. A similar result was shown for HER2 status; the
association of higher DNAm age with a better prognosis
was stronger in HER2 positive than negative patients.
Fig. 1 Correlations between DNAm age and chronological age. a DNAm age of 122 adjacent normal breast tissues from breast cancer patients
can predict chronological age with decent accuracy. The median absolute deviation (MAD) and range of the difference between DNAm age and
chronological age were 5.78 years and − 24.94 to 12.02 years, respectively. b DNAm age of 1097 breast cancers was poorly correlated
with patients’ chronological age. The MAD and range of the difference between DNAm age and chronological age were 14.72 years and
− 67.35 to 91.38 years, respectively
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When stratified by PAM50 subtype, the overall survival
was markedly worse in the patients with HER2-enriched
or Basal-like breast cancer than those with Luminal A or
B breast cancer (P for interaction = 0.016), while this
phenomenon did not occur for recurrence-free survival.
Discussion
Although younger DNAm age of normal tissues was widely
showed to be associated with better health outcomes in
previous studies [7–17], the present study showed that
younger DNAm age in the cancerous tissues of breast
would predict a poorer prognosis. Since a higher DNAm
age means that the individual is at an older age than
chronological age, which is likely induced by harmful envir-
onmental exposures, unhealthy lifestyles, susceptible hered-
ity, or stochastic events, it is reasonable for an accelerated
DNAm age of health tissues to be connected with poorer
health status. However, the situations might be different in
Table 1 Demographic and clinicopathological characteristics and the associations with DNA methylation age for 1076 female breast
cancer patients (N, %)
Characteristics Total DNAm age (quartile)b P
value
aFirst Second Third Fourth
Age (years)
< 40 96 (8.9) 52 (19.3) 20 (7.4) 13 (4.8) 11 (4.1) < 0.01
40–60 496 (46.1) 145 (53.9) 148 (55.0) 115 (42.8) 88 (32.7)
> 60 484 (45.0) 72 (26.8) 101 (37.5) 141 (52.4) 170 (63.2)
Race
African American 178 (16.5) 72 (26.8) 40 (14.9) 35 (13.0) 31 (11.5) < 0.01
White or other 898 (83.5) 197 (73.2) 229 (85.1) 234 (87.0) 238 (88.5)
Menopausal status
Premenopausal 229 (21.3) 80 (29.7) 57 (21.2) 54 (20.1) 38 (14.1) < 0.01
Post-menopausal 736 (68.4) 153 (56.9) 185 (68.8) 187 (69.5) 211 (78.4)
Unknown 111 (10.3) 36 (13.4) 27 (10.0) 28 (10.4) 20 (7.4)
ER
Negative 178 (16.6) 99 (36.8) 53 (19.7) 20 (7.4) 6 (2.2) < 0.01
Positive 588 (54.6) 95 (35.3) 140 (52.0) 161 (59.9) 192 (71.4)
Unknown 310 (28.8) 75 (27.9) 76 (28.3) 88 (32.7) 71 (26.4)
PR
Negative 251 (23.3) 122 (45.4) 67 (24.9) 36 (13.4) 26 (9.7) < 0.01
Positive 512 (47.6) 70 (26.0) 126 (46.8) 145 (53.9) 171 (63.6)
Unknown 313 (29.1) 77 (28.6) 76 (28.3) 88 (32.7) 72 (26.7)
HER2
Negative 644 (59.9) 156 (58.0) 162 (60.2) 155 (57.6) 171 (63.5) 0.33
Equivocal/positive 118 (11.0) 37 (13.7) 31 (11.5) 24 (9.0) 26 (9.7)
Unknown 314 (29.1) 76 (28.3) 76 (28.3) 90 (33.4) 72 (26.8)
PAM50
Luminal A 229 (21.3) 25 (9.3) 51 (19.0) 71 (26.4) 82 (30.5) < 0.01
Luminal B 122 (11.3) 22 (8.2) 25 (9.3) 28 (10.4) 47 (17.5)
HER2-enriched & Basal-like 155 (14.4) 84 (31.2) 41 (15.2) 22 (8.2) 8 (3.0)
Unknown 570 (53.0) 138 (51.3) 152 (56.5) 148 (55.0) 132 (49.0)
Clinical stage
I/II 568 (52.8) 136 (50.6) 149 (55.4) 136 (50.6) 147 (54.6) 0.26
III/IV 187 (17.4) 56 (20.8) 38 (14.1) 44 (16.3) 49 (18.2)
Unknown 321 (29.8) 77 (28.6) 82 (30.5) 89 (33.1) 73 (27.1)
a Pearson chi-squared test. Unknown data was not accounted in the test
bPatients were divided into quartiles according to DNAm age. First quartile: 2.2–37.6; Second quartile: 37.7–49.8; Third quartile: 49.9–64.9; Fourth quartile: 65–157
Significant ones are in boldface
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cancerous tissues. As we know, carcinogenesis was an evo-
lutionary process, driven by stepwise, somatic cell muta-
tions with sequential, sub-clonal selection, forming the
so-called cancer stem cells with potential to proliferation
and propagation [22, 23]. Like DNAm age of stem cells
which was low and increased with the propagation in na-
ture, lower DNAm age of cancer cells might present more
vicious tumor with a more potential to proliferate [6],
which supports our present result of the association be-
tween younger DNAm age and poorer prognosis of breast
cancer. In addition, this result was also consistent with the
following two facts: lower DNAm age in cancer cells was
associated with higher rates of genetic mutations, including
P53 [6]; black breast cancer patients had a worse cancer-
free interval than white patients, while the formers had a
lower DNAm age than the later ones [24].
The associations between DNAm age and overall sur-
vival had ever been explored in several other tumors by
Lin and Wagner and the associations were varied by the
tumors derived organs [18]. The overall survival was
more likely to be better in patients with esophageal car-
cinoma or glioblastoma multiforme if the DNAm age
was older, which is in line with the result of present
study, while a better prognosis with a younger DNAm
age was showed in patients with thyroid carcinoma or
renal clear cell carcinoma. There were no significant as-
sociations for cancers of lung, pancreas, skin, uterine,
colon, bladder, et al. Based on these results, Lin and
Table 2 Association of overall and five-year survival with DNA methylation age
DNAm Age N Overall survival Five-year survival
HR (95% CI) a HR (95% CI) b HR (95% CI) c HR (95% CI) a HR (95% CI) b HR (95% CI) c
Continuous
(Per ten year) 1076 1.01 (0.94–1.08) 0.92 (0.85–1.00) 0.94 (0.86–1.02) 0.92 (0.84–1.01) 0.84 (0.75–0.93) 0.85 (0.76–0.96)
Categorical (quartile) d
First 269 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Second 269 0.80 (0.51–1.26) 0.66 (0.42–1.05) 0.64 (0.39–1.04) 0.59 (0.34–1.03) 0.49 (0.28–0.85) 0.52 (0.29–0.92)
Third 269 0.79 (0.51–1.24) 0.56 (0.35–0.89) 0.56 (0.34–0.93) 0.66 (0.39–1.12) 0.46 (0.27–0.78) 0.49 (0.27–0.87)
Fourth 269 1.00 (0.66–1.53) 0.56 (0.35–0.90) 0.60 (0.36–1.04) 0.60 (0.34–1.03) 0.33 (0.18–0.59) 0.38 (0.20–0.72)
P for trend 0.939 0.014 0.065 0.075 0.001 0.004
Categorical (First quartile and second-fourth quartile)
First 269 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Second-Fourth 807 0.86 (0.61–1.22) 0.59 (0.41–0.86) 0.60 (0.40–0.91) 0.61 (0.41–0.93) 0.42 (0.27–0.65) 0.47 (0.29–0.76)
aNo adjustment
bAdjusted only for chronological age (continuous)
cAdjusted for chronological age (continuous), race, clinical stage, menopause status, ER status, HER2 status and PAM50 subtype
dPatients were divided into quartiles according to DNAm age. First quartile: 2.2–37.6; Second quartile: 37.7–49.8; Third quartile: 49.9–64.9; Fourth quartile: 65–157
Significant ones are in boldface
Table 3 Association of recurrence free survivals with DNA methylation age
DNAm Age N Overall recurrence free survival Five-year recurrence free survival
HR (95% CI) a HR (95% CI) b HR (95% CI) c HR (95% CI) a HR (95% CI) b HR (95% CI) c
Continuous
(Per ten year) 889 0.89 (0.81–0.98) 0.86 (0.77–0.96) 0.86 (0.76–0.97) 0.87 (0.78–0.98) 0.84 (0.75–0.95) 0.86 (0.75–0.98)
Categorical (quartile) d
First 215 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Second 230 0.82 (0.48–1.39) 0.76 (0.44–1.31) 0.77 (0.43–1.36) 0.77 (0.43–1.36) 0.70 (0.39–1.25) 0.71 (0.39–1.31)
Third 227 0.82 (0.49–1.37) 0.72 (0.42–1.23) 0.70 (0.39–1.29) 0.76 (0.43–1.36) 0.65 (0.36–1.17) 0.68 (0.36–1.32)
Fourth 217 0.48 (0.25–0.90) 0.40 (0.21–0.78) 0.39 (0.19–0.80) 0.39 (0.19–0.80) 0.31 (0.15–0.66) 0.32 (0.14–0.74)
P for trend 0.031 0.009 0.014 0.014 0.003 0.020
Categorical (First quartile and second-fourth quartile)
First 215 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Second-Fourth 674 0.71 (0.46–1.08) 0.64 (0.41–1.00) 0.66 (0.39–1.09) 0.64 (0.40–1.02) 0.57 (0.35–0.93) 0.62 (0.35–1.07)
aNo adjustment
bAdjusted only for chronological age (continuous)
cAdjusted for chronological age (continuous), race, clinical stage, Menopause Status, ER status, HER2 status and PAM50 subtype
dPatients were divided into quartiles according to DNAm age. First quartile: 2.2–37.6; Second quartile: 37.7–49.8; Third quartile: 49.9–64.9; Fourth quartile: 65–157
Significant ones are in boldface
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Wagner speculated that alterations of DNAm age could
resemble a double edged sword [18]: on the one hand,
the alterations may provide a barrier of proliferation for
aging cells and prevent cancer initiation; on the other
hand, they could also favor chromosomal changes that
trigger other mutations, which might be the reason why
increased DNAm age in different cancers had various ef-
fects on the prognosis. In the present study, it was also
found that patients with different subtypes of breast
cancer, such as Luminal A or B and HER2 enriched or
Basal-like, had opposite associations between the DNAm
age and the prognosis. Nevertheless, the comprehensive
associations of DNAm age with various cancers or sub-
types and the mechanisms are remained to be explored.
We further found that the association of higher
DNAm age with a better prognosis might be stronger in
post-menopausal than pre-menopausal patients, which
was supported to some extent by the results in a recent
Table 4 Associations of overall survival and recurrence free survivals with DNA methylation age stratified by menopause and
clinicopathological features
Stratified variables DNAm age
(quartile)a
Survival Recurrence
N HRb (95% CI) N HRb (95% CI)
Menopause Status
Pre First 80 1.00 (ref) 72 1.00 (ref)
Second-Fourth 149 0.87 (0.30–2.58) 133 1.16 (0.42–3.21)
Post First 153 1.00 (ref) 117 1.00 (ref)
Second-Fourth 583 0.40 (0.24–0.69) 486 0.58 (0.29–1.16)
P for interaction 0.3761 0.963
Clinical stage
Stage I&II First 136 1.00 (ref) 103 1.00 (ref)
Second-Fourth 432 1.24 (0.62–2.49) 341 0.80 (0.32–1.96)
Stage III&IV First 56 1.00 (ref) 39 1.00 (ref)
Second-Fourth 131 0.39 (0.17–0.91) 97 1.07 (0.39–2.92)
P for interaction 0.159 0.665
ER status
negative First 99 1.00 (ref) 77 1.00 (ref)
Second-Fourth 79 0.82 (0.31–2.15) 61 0.60 (0.19–1.84)
positive First 95 1.00 (ref) 67 1.00 (ref)
Second-Fourth 493 0.54 (0.29–0.99) 385 0.77 (0.33–1.78)
P for interaction 0.092 0.9972
HER2 status
negative First 156 1.00 (ref) 119 1.00 (ref)
Second-Fourth 488 0.92 (0.51–1.64) 382 1.14 (0.57–2.31)
Equivocal /positive First 37 1.00 (ref) 25 1.00 (ref)
Second-Fourth 81 0.37 (0.09–1.58) 63 0.18 (0.03–1.21)
P for interaction 0.217 0.133
PAM50
Luminal A First 25 1.00 (ref) 13 1.00 (ref)
Second-Fourth 204 0.72 (0.17–2.97) 149 0.59 (0.11–3.24)
Luminal B First 22 1.00 (ref) 16 1.00 (ref)




First 84 1.00 (ref) 61 1.00 (ref)
Second-Fourth 71 1.91 (0.67–5.41) 48 0.66 (0.17–2.53)
P for interaction 0.016 0.966
a Patients were divided into quartiles according to DNAm age. First quartile: 2.2–37.6; Second quartile: 37.7–49.8; Third quartile: 49.9–64.9; Fourth quartile: 65–157
b Adjusted for chronological age (continuous), race, clinical stage, menopause Status, ER status, HER2 status and PAM50 subtype. When one of the confounders
was the variable for stratifying, it was not adjusted in the model
Significant ones are in boldface
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published report in which accelerated DNAm age was
found to be associated with breast cancer susceptibility
only in postmenopausal but not pre-menopausal women
[25]. It suggests that hormones may influence the associ-
ations between DNAm age and the initiation and devel-
opment of breast cancer and the DNAm age may reflect
the real biological age in a less-hormone condition. This
is also supported by the facts that the DNAm age of fe-
male breast tissue is higher than that of their blood cells
and the difference diminishes with increasing age [26]. It
may also be explained by the roles of the age-associated
compromised detoxification, DNA repair mechanisms
and immune surveillance [27].
In the present analysis, we adjusted various factors and
applied several outcomes, and the associations between
DNAm age and breast cancer prognosis were consistent
and quite strong. Chronological age seemed play a nega-
tive confounding role and the association between
DNAm age and breast cancer prognosis was stronger
when adjusted by chronological age, which can be ex-
plained by the facts that breast cancer prognosis was
getting worse with the increase of chronological age
[28], while DNAm age in tumors had a positive relation-
ship with chronological age. However, the relationship
between DNAm age in tumors and chronological age
was weak and the negative effect on the association be-
tween DNAm age and breast cancer prognosis was not
fundamental (as shown in Tables 2 and 3). As for the
clinicopathological features, although the statuses of
hormone receptors (ER and PR) and PAM50 subtype
were associated with DNAm age, they only had a minor
effect on the associations between DNAm age and breast
cancer prognosis, indicating that the effect of DNAm
age on breast cancer prognosis was not likely to mediate
through the clinicopathological features.
We used four types of outcomes for breast cancer
prognosis: overall survival, overall recurrence free sur-
vival, five-year survival, and five-year recurrence free
survival, which have different clinical meanings. Overall
survival means any survived patients including those
who died of breast cancer as well as other diseases; the
longer the time elapsed, the more patients died of other
diseases. Therefore, the (five-year) recurrence free sur-
vivals might be better outcomes to estimate the progno-
sis specific to breast cancer, in which there was an
obvious dose-response relationship between DNAm age
and the outcomes (as shown in Table 3).
Conclusion
In summary, the present study found that DNAm age
of the tumor tissue, which associated with menopausal
status and pathological features, was a strong independ-
ent predictor of breast cancer prognosis. These results
suggested that the prognosis of breast cancer was
related to intrinsic biological changes, and specific mo-
lecular targets for treatment of breast cancer may be
implicit, particularly for that DNAm changes are of
interest suggesting possible rejuvenation and health
maintenance due to the reversibility [29]. The exact
mechanisms and related genetic or environmental fac-
tors for the DNAm age remain to be explored.
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